Skip to content
Tech News
← Back to articles

Evvy secures $40M Series B to expand vaginal microbiome testing and research

read original get Evvy Vaginal Microbiome Test Kit → more articles
GoKawiil Brief

Evvy, a women's health startup, has closed a $40 million Series B funding round led by Catalio Capital Management. The company operates an at-home vaginal microbiome test that uses mNGS sequencing, serving over 100,000 patients and 3,000 practitioners across the US, and has produced 15 peer-reviewed publications from its data.

Why It Matters

GoKawiil's interpretation of the reporting above, not reported fact.

Evvy's approach highlights a broader gap in medical research: female biology has historically been underrepresented in datasets used to build precision medicine and AI health tools. By amassing microbiome data linked to symptoms and outcomes, the company aims to create a foundation for more accurate, personalized care for women, addressing a blind spot that even advanced AI models currently struggle to fill.

Key Takeaways
Worth a Look

Evvy Vaginal Microbiome Test Kit — If you're curious about the at-home testing technology discussed in this article, Evvy's vaginal microbiome test lets you send a single swab to their lab for detailed mNGS analysis. It's a direct way to engage with the same personalized health data and clinician-reviewed insights that fueled this company's growth and research breakthroughs.

See Evvy Vaginal Microbiome Test Kit on Amazon → Affiliate link — we may earn a commission on purchases, at no extra cost to you. Product picked by AI based on this article; it is not a tested recommendation.

Source: techcrunch.com — Dominic-Madori Davis, 2026-09-15

Published there as: “Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data”

Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.